Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

Body mass index (BMI) may not provide the most accurate screening for skeletal muscle deficits among youth with pediatric‐onset inflammatory bowel disease (IBD), according to a study in the Journal of ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

Treatment with RBL was effective against recurrent CDI among high-risk patients when administered at home or in clinical settings.

The US FDA says it plans to use artificial intelligence to help speed the approval of new drugs and medical devices.

The vaccine is expected to be commercially ready for the 2025-2026 COVID-19 season. The Food and Drug Administration (FDA) has approved Nuvaxovid ™ (COVID-19 Vaccine, Adjuvanted) for active ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

Janus kinase (JAK) inhibitors are not associated with an increased risk for gastrointestinal perforation (GIP) among patients with rheumatoid arthritis (RA), according to study results published in ...

While CVS hospitalizations have declined, the illness continues to present among young women, Black individuals, and leads to high costs among Hispanic patients.

Adding perioperative systemic therapy to CRS-HIPEC can improve some outcomes in patients with resectable colorectal peritoneal metastases, data suggest.

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.